<DOC>
	<DOCNO>NCT02450981</DOCNO>
	<brief_summary>This clinical study phase 1 study carry evaluate safety , pharmacokinetics tolerability multiple intravitreal injection BCD-021 ( bevacizumab biosimilar candidate manufacture CJSC BIOCAD , Russia ) use patient neovascular wet age-related macular degeneration .</brief_summary>
	<brief_title>Evaluation Pharmacokinetics , Safety , Tolerability BCD-021 Patients With Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description>BCD-021-1 open label , non-comparative , non-randomized , multicenter phase 1 clinical study evaluate pharmacokinetics , safety tolerability multiple intravitreal injection BCD-021 ( bevacizumab biosimilar , CJSC BIOCAD ) give patient exudative ( wet ) age-related macular degeneration . The study enrol 10 patient confirm neovascular wet age-related macular degeneration . Before inclusion active phase study , patient undergo diagnostic examination screen period maximum duration 28 day . The principal part study include period first intravitreal injection 28 day third intravitreal injection . The goal stage evaluate pharmacokinetics , safety tolerability multiple intravitreal injection BCD-021 ( CJSC BIOCAD , Russia ) use patient neovascular wet age-related macular degeneration . Extension phase study ( month 4 - month 12 ) require assess long-term effect therapy get full information immunogenicity study drug .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>subject provide informed consent ; men woman ; patient must 50 year old ; wet AMD study eye , define active choroidal neovascular membrane ( CNV ) ( previously treat intravitreal injection antiVEGF drug ) , include retinal angiomatous proliferation ( RAP ) , oedema involve fovea demonstrate optical coherence tomography ( OCT ) ; best correct VA study eye range 20/32 ( 6.3/10 ) 20/320 ( 0.6/10 ) ETDRS scale ; size lesion &lt; 12 disk area ; case occult neovessels , proof require recent development lesion : loss VA least 5 letter ETDRS last 3 month OR appearance subretinal hemorrhage OR increase size lesion ( &gt; 10 % ) use fluorescein angiography last month comparison last 3 month OR appearance OCT criterion macular oedema type , serous separation neuroepithelium , separation pigment epithelial last month inclusion trial ; one eye study patient may recruit study ; patient 's ability follow protocol procedure ; male female patient normal reproductive function sexual partner aware willing use voluntarily reliable method contraception whole period study include screening period . Previous current treatment intravitreal injection antiVEGF drug ( ranibizumab , bevacizumab , aflibercept pegaptanib , etc . ) ; Other heal treatment study eye last 3 month first injection ; Former vitrectomy study eye ; Medical history photocoagulation study eye ; Involvement another clinical study ( study eye and/or eye ) ; Subretinal hemorrhage reach fovea centre , size &gt; 50 % lesion area ; Fibrosis retrofoveal retinal atrophy study eye ; Retinal pigment epithelial tear reach macula study eye ; Choroidal neovascularisation relate AMD study eye ; Medical history intravitreal medical device study eye ; Active suspect ocular periocular infection ; Acute conjunctivitis , keratitis , scleritis , endophthalmitis ; Serious active intraocular inflammation study eye ; Maculaforamen study eye ; Myopia large 8 diopter ; Former corneal graft study eye ; Medical history autoimmune idiopathic uveitis ; Proved diabetic retinopathy ; Intraocular pressure â‰¥ 25 mmHg despite two topical hypotonic treatment ; Medical history intraocular surgery within 2 month first injection study eye ; Aphakia lack lens capsule ( remove laser ) study eye ; Any illness ocular condition would require intraocular surgery study eye within 12 month inclusion ; Known hypersensitivity bevacizumab another drug composite medicinal product use ; allergy anaesthetic eye drop ; Arterial hypertension control appropriate treatment ; Previous current treatment systemic administration bevacizumab ; Pregnancy breastfeeding ; Any determine immunodeficiency ; Syphilis , HIV , hepatitis B , history hepatitis C virus ; Any mental disorder create risk patient influence patient 's ability follow study protocol ; Drug addiction , alcoholism . Presence history malignant neoplasm ( include lymphoproliferative disease ) ; Simultaneous participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>